Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy

Opthea Limited Sponsored ADR (OPT) has released an update.

Opthea Limited is set to make a significant impact at the upcoming 24th EURETINA Congress with presentations and a symposium on sozinibercept, a novel treatment for wet AMD that shows promise in outperforming current therapies. The company has completed patient enrollment for Phase 3 trials of sozinibercept and anticipates releasing topline data in early and mid-2025. These developments could position sozinibercept as the first new therapy in two decades to improve visual outcomes for wet AMD patients.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.